Site icon Market Globalist

What Has Uplifted the CytoDyn (CYDY) Stock 15% In The Last Session?

AMHC

AMHC

Stock late-stage biotechnology company CytoDyn Inc. (OTCQB: CYDY) surged by 14.95% in the last session bring the share price to $2.46 at the close of the market. The stock has been trading in a day range of $2.5700 to $2.0000.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

Performance in brief:

A share price decline of over -61.51% occurred in the last month; with more than 6.28 million shares on average traded in that time. If we look at the performance of CYDY stock over three months, the stock plunged by -21.66% with 5.81M shares traded on average. Stock price in the last 12 months has grown by over 152.53%, with a high of $10.010 and a market cap of $1.50B.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

Company’s profile:

This late-stage biotech firm develops innovative treatments based on humanized monoclonal antibodies targeted to the CCR5, the target of the company’s new treatment, leronlimab. There is strong evidence that CCR5 plays a vital role in the ability for HIV to enter healthy T-cells and infect them. Furthermore, the CCR5 receptor has been implicated in infectious diseases such as GvHD and NASH, in addition to tumor metastasis.

What took the stock higher?

CytoDyn Inc., in a press release today announced the administration of a dosage of in Phase 2 trial being conducted by the company currently. Stocks rose in the last trading session as a result of this positive news. Following are some highlights from the company’s press release about the ongoing trials:

Last but not least,

CytoDyn Inc. (CYDY) believes that leronlimab will succeed for many indications, thanks to strong CD12 results and NASH and long-hauler data that are at the forefront of the pipeline, and its potential for HIV just around the corner. And that will not only be improving the returns of CYDY’s shareholders but will also bolster the company’s growth.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Exit mobile version